Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Cash from Financing Activities: 2009-2024

Historic Cash from Financing Activities for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Dec 2024 value amounting to -$107.0 million.

  • Ironwood Pharmaceuticals' Cash from Financing Activities rose 100.18% to $88,000 in Q2 2025 from the same period last year, while for Jun 2025 it was -$41.9 million, marking a year-over-year increase of 78.02%. This contributed to the annual value of -$107.0 million for FY2024, which is 138.60% down from last year.
  • Ironwood Pharmaceuticals' Cash from Financing Activities amounted to -$107.0 million in FY2024, which was down 138.60% from $277.2 million recorded in FY2023.
  • Ironwood Pharmaceuticals' 5-year Cash from Financing Activities high stood at $277.2 million for FY2023, and its period low was -$237.6 million during FY2022.
  • In the last 3 years, Ironwood Pharmaceuticals' Cash from Financing Activities had a median value of -$107.0 million in 2024 and averaged -$22.5 million.
  • As far as peak fluctuations go, Ironwood Pharmaceuticals' Cash from Financing Activities skyrocketed by 1,665.06% in 2020, and later slumped by 5,120.95% in 2022.
  • Over the past 5 years, Ironwood Pharmaceuticals' Cash from Financing Activities (Yearly) stood at $18.5 million in 2020, then plummeted by 124.53% to -$4.5 million in 2021, then plummeted by 5,120.95% to -$237.6 million in 2022, then surged by 216.67% to $277.2 million in 2023, then tumbled by 138.60% to -$107.0 million in 2024.